FDA Extends Review of Omaveloxolone in Friedreich Ataxia

August 9, 2022. After Reata Pharmaceuticals submitted an analysis from the MOXIe extension study of the investigational agent as part of the NDA submission, the FDA extended the PDUFA date to February 2023.

FDA Extends Review of Omaveloxolone in Friedreich Ataxia